Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | P.R. Clingan, A.M. Mant, G.E. Richardson, D.M. Kowalski, P. Koralewski, I. Lugowska, A. Dechaphunkul, C. Charoentum, A. Sookprasert, V. Sriuranpong, A. Akopov, V. Kozlov, N. Fadeeva, B. Kasparov, N.V. Kovalenko, V. Oschepkov, L. Gorelik, Y. Kunes, J. Oliviero , D.L. Harris | ||||||||||||
Title | Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers | ||||||||||||
|
|||||||||||||
URL | https://www.annalsofoncology.org/article/S0923-7534(19)58691-4/pdf | ||||||||||||
Abstract Text | Ann Oncol. Oct 2019, Vol 30 (Suppl_5): v177 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cosibelimab | Cosibelimab | 0 | 2 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cosibelimab | CK-301|CK 301|TG-1501|TG1501|TG 1501 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | Cosibelimab (CK-301) is a human monoclonal antibody against PD-L1 (CD274), which may block immune checkpoint, lead to anti-tumor immune response (Ann Oncol. Oct 2019, Vol 30 (Suppl_5): v177). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|